Patricia Marinello

Pembrolizumab (MK-3475) in combination with lenalidomide and low-dose dexamethasone for relapsed/refractory multiple myeloma (RRMM): KEYNOTE-023

Meeting abstracts The immunomodulatory drug (IMiD) lenalidomide has single-agent activity against RRMM, and synergistic effects when combined with dexamethasone. Overexpression of PD-L1 is associated with tumor invasiveness in MM cells and may be a mechanism of immune evasion. Pembrolizumab, a

An open-label, multicohort Phase Ib trial of pembrolizumab (MK-3475) for advanced hematologic malignancies: KEYNOTE-013

Meeting abstracts Tumors, including hematologic malignancies, can use the PD-1 pathway to evade immune surveillance. Pembrolizumab, a highly selective, humanized monoclonal antibody that blocks interaction of PD-1 with its ligands PD-L1 and PD-L2, has demonstrated robust antitumor activity and a

Anti-PD1 associated fulminant myocarditis after a single pembrolizumab dose: the role of occult pre-existing autoimmunity

Multiple myeloma is a promising candidate for anti-PD1 checkpoint inhibitor therapy.[1][1]–[3][2] Results of phase I trials of pembrolizumab, in combination with lenalidomide or pomalidomide in relapsed/refractory patients have shown encouraging results. These trials showed a 35% and 65% response